BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform aimed at the rapidly growing $4 billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. PURE EP is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time. PURE EP acquires and displays high-fidelity cardiac signal recordings even at undetectable levels (until now) with high-accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of repeat procedures.

**Executive Summary**

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform aimed at the rapidly growing $4 billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. PURE EP is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time. PURE EP acquires and displays high-fidelity cardiac signal recordings even at undetectable levels (until now) with high-accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of repeat procedures.

**Current Problem: Cardiac Arrhythmias (1 in 18 or 14.4M Americans)^1**

Two of the most prevalent and deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). Ventricular arrhythmias account for more than 450,000 sudden deaths per year in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting as many as 6.1 million people in the U.S. and is expected to grow to 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B.

**Current treatments lack efficacy/efficiency**

- **Anti-Arrhythmic Drug Therapies**
  - Limited Effectiveness
  - Detrimental Side Effects

- **Catheter Ablation Procedures**^2
  - Remains Mostly Anatomical
  - Procedures are Long (2-8 Hours)
  - Active Scars are Difficult to Detect
  - Multiple Procedures Typically Required

- **Electrophysiology (EP) procedures**: For diagnostic EP studies, catheters are advanced through a patient’s vessels and placed on cardiac tissue to record intracardiac signals. During ablation treatments, RF energy is applied to cardiac tissue to destroy abnormal electrical pathways. *American Heart Association data

**BioSig’s Solution: PURE EP**

The success of catheter ablation treatment decisions is highly dependent on the quality and levels of ECG and intracardiac electrogram signals.

**PURE EP’s Novel Approach:**

- PURE EP System is different from current recording systems: its proprietary hardware and signal processing provides enhanced real-time information
- Offers improved clarity of acquired cardiac data even at the very low, (until now) undetectable signal levels for better clinical decisions and diagnostics/outcomes

**Company Statistics**

- **Ticker**: BSGM (OTCQB)
- **Headquarters**: Minneapolis, MN
- **Price**: $1.36 (06/01/17)
- **52 Week Range**: $1.05 – $2.00
- **Avg. Daily Volume (30 day)**: 48,327
- **Shares Outstanding**: 25.22 Million
- **Market Cap**: $34.3 Million
- **Float**: 12.2 Million free trading shares

**Investment Highlights**

- Completed $5 million private placement in 2017
- 10-year Unique Collaboration with Mayo Clinic
- Anticipated Uplisting to a Senior Exchange in 2017
- Proven Management Team & Board of Director
- World-Class Scientific Advisory Board
- EP Devices: $4+B TAM, 10% Growth
- Large Cardiac Arrhythmia Patient Population; Ablations Growing 10%+^4
- Increasing Demand for New EP Technologies to Address:
  - Unacceptably High Recurrence Rates (31% - 46%)^5
  - Complex Ablation Treatments
  - High Costs with Shorter Procedure Times & Higher Patient Throughput
- High-Growth Sector Earns Innovation Premium, Aggressive M&A
- PURE EP System Testing is underway at Mayo Clinic & Mt Sinai
- **BioSig is collaborating with leading EPs from:**
  - Texas Cardiac Arrhythmia Institute
  - UCLA Cardiac Arrhythmia Center
  - U.H. Case Medical Center - Cleveland
  - Bringham and Women’s Hospital - Boston
  - Mount Sinai Medical Center - NYC
  - Mayo Clinic - Minnesota & FL

**Investment Catalysts**

**$4 Billion Market Opportunity: Fast Growing - Addressable**

The most recent MD&D report shows the global Electrophysiology (EP) market revenues will grow more than 10% annually, from currently $4 billion to approximately $6 billion by 2020 with accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020. Procedure growth in the United States alone is projected at an 11.0% annual rate, from 250,000 in 2015 to 422,000 in 2020. This is accompanied by an 11.7% growth in revenues, from $1.85 billion in 2015 to $3.220 billion in 2020. The FDA (www.fda.gov) recently presented at the Heart Rhythm Society 2017 and spoke of the importance of technological innovation in the EP field.

**Growth Strategy**

BioSig will seek FDA 510(k) clearance for its PURE EP System. The Company has achieved proof of concept validation through UCLA, and has performed and continues to perform pre-clinical studies at Mayo Clinic in Minnesota and Mt Sinai in NY. BioSig is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, and Bringham and Women’s Hospital in Boston to develop, refine and, ultimately, commercialize its novel information system.

**Price & Float:**

- **52 Week Range**: $1.05 – $1.76
- **Price & volume quotes from Yahoo! Finance and other reliable sources**

**$4 Billion Market with 10% Growth**

Revenues will grow more than 10% annually, from currently $4 billion to approximately $6 billion by 2020^3
PURE EP System

- Information Unobtainable from Any Other EP Device Today
- Proprietary Hardware / Signal Processing Capabilities / Ability to Open Multiple Review Windows
- To Assist in Clinical Decision Making in Real-Time
- To Maximize Ablation Efficacy & Minimize Need for Repeat Procedures
- To Shorten & Simplify EP Procedures
- Increased Accuracy – Noise-canceling (interference)

PURE EP System is a novel platform designed to provide real-time, precise, and uninterrupted information for clinical decision-making during electrophYSiology studies and ablation procedures. The PURE EP System utilizes the latest innovative technology that is sorely needed in an industry that uses 10+ year old technologies. The PURE EP System has estimated FDA clearance Q4 2017 As demand continues to grow in the field, the PURE EP System is positioned perfectly for long-term success. In February 2016, BioSig initiated a development deal for its PURE EP system with Minnetronix, an award-winning medical technology development and manufacturing firm.

Proven Management Team & Board of Directors

BioSig is comprised of a stellar cast of a proven management team with a world-class Scientific Advisory Board and a premier Board of Directors, many of who have continued to invest their own cash into the Company. BioSig brought together leading executives, doctors and scientists from prominent hospitals, healthcare programs, Fortune 500 Companies and elite educational institutions including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Boston Scientific, Celgene, Medtronic, St. Jude Medical, J.P. Morgan and GE Healthcare, to name a few. Kenneth L. Londoner, the Co-Founder, Chief Executive Officer, Chairman and Director has a wealth of knowledge and experience that spans many decades and includes founding, running, and serving as Director to many key Companies. Mr. Londoner began his career with J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing $3.5 billion in mutual funds, pension funds, and international assets. Steve Chaussy, CFO has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance; and Mr. Chaussy served as CFO for a large private distribution and wholesaling company, where he gained international experience. Their many accomplishments and years of experience of the management team, as well as the Board of Directors and Scientific Advisory Board, is unmatched and provides BioSig a clear advantage in the market.

Expanding IP Portfolio

BioSig filed two provisional patent applications in 2016 – Assessment of Catheter Position by Local Electrogram and Visualization of Conduction Tissue Signals; significant potential exists to continue to strengthen its intellectual property position with the 10-year collaboration with Mayo Clinic physicians.

Trade Publications – Published Data

BioSig has had key publications write pieces on the technology, BioSig has been written up by Medical Device Daily, MD+DI (Medical Device and Diagnostic Industry), Medcity News, and BioSpace, to name a few. BioSig’s Enhanced Electrophysiology Recording Improves Signal Acquisition was presented by the Mayo team at the 13th Annual International Dead Sea Symposium; Novel Electrophysiology Signal Recording System Enables Specific Visualization of Purkinje Network and Other High Frequency Signals was published in the Journal of the American College of Cardiology: Clinical Electrophysiology (JACC:CEP) and on its list of the top five most influential articles in 2016: Enhanced Electrophysiology Recording System was presented at the 38th Annual Conference of the IEEE - EMBC 2016. Use of Terminal Unipolar Electrogram Current of Injury as a Novel Marker to Estimate Contact: An Acute Canine Study was a poster presentation at HRS 38th Annual Scientific Sessions May 11, 2017 in Chicago. Initial Experience with the BioSig PURE EP™ Signal Recording System: An Animal Laboratory Experience was published in The Journal of Innovations in Cardiac Rhythm Management, April 2017.

Analyst Coverage

<table>
<thead>
<tr>
<th>Laidlaw &amp; Co (UK) Ltd.</th>
<th>Goldman Small Cap Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target: $4.00</td>
<td>Price Target: $5.00</td>
</tr>
<tr>
<td>Amit Tandon</td>
<td>SeeThruEquity</td>
</tr>
<tr>
<td>Stock Rating: Buy</td>
<td>Price Target: $3.53</td>
</tr>
</tbody>
</table>

Disclaimer: This Corporate Summary Sheet includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approval; competition and marketplace demand. More information, and BioSig risk factors, are set forth in its Rings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.